MX2023006939A - Dosificacion de fedratinib. - Google Patents
Dosificacion de fedratinib.Info
- Publication number
- MX2023006939A MX2023006939A MX2023006939A MX2023006939A MX2023006939A MX 2023006939 A MX2023006939 A MX 2023006939A MX 2023006939 A MX2023006939 A MX 2023006939A MX 2023006939 A MX2023006939 A MX 2023006939A MX 2023006939 A MX2023006939 A MX 2023006939A
- Authority
- MX
- Mexico
- Prior art keywords
- fedratinib
- dosing
- cyp2c19
- dual
- present disclosure
- Prior art date
Links
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 title 1
- 229950003487 fedratinib Drugs 0.000 title 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 abstract 1
- 208000007667 Cytochrome P-450 CYP2C19 Inhibitors Diseases 0.000 abstract 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 abstract 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 abstract 1
- 208000014767 Myeloproliferative disease Diseases 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente descripción proporciona métodos para tratar trastornos mieloproliferativos en pacientes que reciben simultáneamente un inhibidor dual de CYP2C19 y CYP3A4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063126289P | 2020-12-16 | 2020-12-16 | |
PCT/US2021/063563 WO2022132933A1 (en) | 2020-12-16 | 2021-12-15 | Dosing of fedratinib |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023006939A true MX2023006939A (es) | 2023-08-08 |
Family
ID=80050729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023006939A MX2023006939A (es) | 2020-12-16 | 2021-12-15 | Dosificacion de fedratinib. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240058336A1 (es) |
EP (1) | EP4262770A1 (es) |
JP (1) | JP2024501640A (es) |
KR (1) | KR20230142468A (es) |
CN (1) | CN116829136A (es) |
AU (1) | AU2021401681A1 (es) |
CA (1) | CA3199509A1 (es) |
CL (1) | CL2023001740A1 (es) |
IL (1) | IL303118A (es) |
MX (1) | MX2023006939A (es) |
WO (1) | WO2022132933A1 (es) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
KR20210102192A (ko) | 2018-09-25 | 2021-08-19 | 임팩트 바이오메디신스, 인코포레이티드 | 골수증식성 장애를 치료하는 방법 |
US20230250068A1 (en) | 2019-02-12 | 2023-08-10 | Inpact Biomedicines, Inc. | Crystalline forms of a jak2 inhibitor |
-
2021
- 2021-12-15 EP EP21848350.1A patent/EP4262770A1/en active Pending
- 2021-12-15 JP JP2023536482A patent/JP2024501640A/ja active Pending
- 2021-12-15 MX MX2023006939A patent/MX2023006939A/es unknown
- 2021-12-15 CN CN202180092903.5A patent/CN116829136A/zh active Pending
- 2021-12-15 US US18/257,770 patent/US20240058336A1/en active Pending
- 2021-12-15 WO PCT/US2021/063563 patent/WO2022132933A1/en active Application Filing
- 2021-12-15 IL IL303118A patent/IL303118A/en unknown
- 2021-12-15 KR KR1020237024162A patent/KR20230142468A/ko unknown
- 2021-12-15 AU AU2021401681A patent/AU2021401681A1/en active Pending
- 2021-12-15 CA CA3199509A patent/CA3199509A1/en active Pending
-
2023
- 2023-06-14 CL CL2023001740A patent/CL2023001740A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4262770A1 (en) | 2023-10-25 |
US20240058336A1 (en) | 2024-02-22 |
AU2021401681A1 (en) | 2023-06-22 |
CA3199509A1 (en) | 2023-06-23 |
IL303118A (en) | 2023-07-01 |
JP2024501640A (ja) | 2024-01-15 |
KR20230142468A (ko) | 2023-10-11 |
CN116829136A (zh) | 2023-09-29 |
CL2023001740A1 (es) | 2023-11-10 |
WO2022132933A1 (en) | 2022-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
MX2020008559A (es) | Compuestos heterocíclicos como inhibidores de la quinasa. | |
MX2021013218A (es) | Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2. | |
MX2019007256A (es) | Inhibidores de las fosfodiesterasas y métodos de tratamiento microbiano. | |
MX2021013662A (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. | |
JO3134B1 (ar) | مثبطات نشاط akt | |
MX2021008191A (es) | Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña. | |
TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
MX2020009773A (es) | Terapia de combinacion. | |
NZ750974A (en) | Antibody and checkpoint inhibitor combination therapy | |
MX2020012173A (es) | Piridinil y pirazinil-(aza)indolsulfonamidas. | |
PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
MX2022001004A (es) | Inhibidores de enzimas. | |
MX2020003192A (es) | Terapia de combinacion usando un antagonista del receptor de quimiocina tipo 2 (ccr2) y un inhibidor de pd-1/pd-l1. | |
MX2021013974A (es) | Metodos, sistemas y dispositivos de seleccion de pacientes tl1a. | |
MX2021015628A (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso. | |
MX2021012418A (es) | Compuestos heterociclicos y sus usos. | |
PH12020552059A1 (en) | Dosing regimen for the treatment of pi3k related disorders | |
MX2019010981A (es) | Terapias de combinacion para el tratamiento de cancer de mama. | |
TW200631584A (en) | A medicament related to mirtazapine for the treatment of hot flush | |
MX2023001425A (es) | Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. | |
MX2022000811A (es) | Inhibidores de enzimas. | |
MX2023006939A (es) | Dosificacion de fedratinib. | |
MX2018012275A (es) | Inhibidores de quinasa. | |
MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. |